These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

269 related items for PubMed ID: 37574125

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Impact of autologous stem cell transplantation (ASCT) on progression free survival (PFS) in newly diagnosed multiple myeloma patients (NDMM) with high risk cytogenetic abnormalities.
    Guman T, Sykora J.
    Bratisl Lek Listy; 2024; 125(1):9-11. PubMed ID: 38041839
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Tandem Autologous Stem Cell Transplantation Does Not Benefit High-Risk Myeloma Patients in the Maintenance Era: Real-World Results from The Canadian Myeloma Research Group Database.
    Venner CP, Duggan P, Song K, Reece D, Sharma S, Su J, Jimenez-Zepeda VH, McCurdy A, Louzada M, Mian H, Sebag M, White D, Stakiw J, Kotb R, Aslam M, Reiman A, Gul E, Chu MP, Bergstrom D, LeBlanc R.
    Transplant Cell Ther; 2024 Sep; 30(9):889-901. PubMed ID: 38971462
    [Abstract] [Full Text] [Related]

  • 5. [Prognostic factors in newly diagnosed multiple myeloma patients with 1q21 amplification/gain treated with bortezomib-based regimens followed by autologous hematopoietic stem cell transplantation].
    Huang WY, Zou DH, Liu W, An G, Xu Y, Sui WW, Deng SH, Li CW, Liu H, Li J, Qiu LG.
    Zhonghua Xue Ye Xue Za Zhi; 2018 Jun 14; 39(6):496-500. PubMed ID: 30032568
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Complete remission status before autologous stem cell transplantation is an important prognostic factor in patients with multiple myeloma undergoing upfront single autologous transplantation.
    Kim JS, Kim K, Cheong JW, Min YH, Suh C, Kim H, Jo DY, Ryoo HM, Yoon SS, Lee JH, Korean Multiple Myeloma Working Party.
    Biol Blood Marrow Transplant; 2009 Apr 14; 15(4):463-70. PubMed ID: 19285634
    [Abstract] [Full Text] [Related]

  • 10. [Bortezomib-based induction chemotherapy followed by autologous hematopoietic stem cell transplantation and maintenance in 200 patients with multiple myeloma: long-term follow-up results from single center].
    Wu Q, Liu JR, Huang BH, Zou WY, Gu JL, Chen ML, Kuang LF, Zheng D, Xu DR, Zhou ZH, Wang HH, Su C, Tong XZ, Li J.
    Zhonghua Xue Ye Xue Za Zhi; 2019 Jun 14; 40(6):453-459. PubMed ID: 31340616
    [Abstract] [Full Text] [Related]

  • 11. Retrospective analysis of the efficacy and influencing factors of autologous hematopoietic stem cell transplantation for multiple myeloma.
    Zhang BL, Zhou J, Lin QD, Liu YZ, Zhang YL, Gui RR, Song YP, Fang BJ.
    Artif Organs; 2019 Oct 14; 43(10):1028-1034. PubMed ID: 30972806
    [Abstract] [Full Text] [Related]

  • 12. Safety and efficacy of autologous stem cell transplantation in dialysis-dependent myeloma patients-The DIADEM study from the chronic malignancies working party of the EBMT.
    Waszczuk-Gajda A, Gras L, de Wreede LC, Sirait T, Illes A, Ozkurt ZN, Snowden JA, Arat M, Bulabois CE, Niederland J, Sever M, Paneesha S, Potter V, Gadisseur A, Chalopin T, Van Gorkom G, López JM, Kerre T, Drozd-Sokolowska J, Raj K, Hayden PJ, Beksac M, Yakoub-Agha I, McLornan DP, Schönland S.
    Bone Marrow Transplant; 2023 Apr 14; 58(4):424-429. PubMed ID: 36681775
    [Abstract] [Full Text] [Related]

  • 13. Impact of Induction Therapy with VRD versus VCD on Outcomes in Patients with Multiple Myeloma in Partial Response or Better Undergoing Upfront Autologous Stem Cell Transplantation.
    Sidana S, Kumar S, Fraser R, Estrada-Merly N, Giralt S, Agrawal V, Anderson LD, Aljurf M, Banerjee R, Bashey A, Battiwalla M, Beitinjaneh A, Chakraborty R, Chhabra S, Dhakal B, Dholaria B, Hashmi S, Janakiram M, Lee C, Lekakis L, Murthy HS, Parrondo R, Wangjam T, Usmani S, Shah N, Qazilbash M, D'Souza A.
    Transplant Cell Ther; 2022 Feb 14; 28(2):83.e1-83.e9. PubMed ID: 34781066
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Outcomes of Maintenance Therapy with Bortezomib after Autologous Stem Cell Transplantation for Patients with Multiple Myeloma.
    Sivaraj D, Green MM, Li Z, Sung AD, Sarantopoulos S, Kang Y, Long GD, Horwitz ME, Lopez RD, Sullivan KM, Rizzieri DA, Chao NJ, Gasparetto C.
    Biol Blood Marrow Transplant; 2017 Feb 14; 23(2):262-268. PubMed ID: 27856369
    [Abstract] [Full Text] [Related]

  • 16. [The efficacy and safety of bortezomib-based induction regimen before autologous hematopoietic stem cell transplantation in patients with multiple myeloma].
    Li J, Liu JR, Huang BH, Chen M, Zheng D, Xu DR, Zou WY.
    Zhonghua Nei Ke Za Zhi; 2012 Apr 14; 51(4):279-83. PubMed ID: 22781947
    [Abstract] [Full Text] [Related]

  • 17. [A retrospective analysis of 124 patients with multiple myeloma who received up-front autologous hematopoietic cell transplantation following triplet induction therapy].
    Tsukada N, Oda Y, Nomura M, Kasuya Y, Takei T, Sato K, Ogura M, Kikuchi T, Abe Y, Suzuki K, Ishida T.
    Rinsho Ketsueki; 2023 Apr 14; 64(11):1397-1403. PubMed ID: 38072424
    [Abstract] [Full Text] [Related]

  • 18. [Efficacy and prognosis of newly diagnosed multiple myeloma patients treated with bortezomib, lenalidomide and dexamethasone].
    Xu JY, Yan WW, Fan HS, Liu JH, Du CX, Deng SH, Sui WW, Xu Y, Qiu LG, An G.
    Zhonghua Yi Xue Za Zhi; 2022 Aug 16; 102(30):2338-2344. PubMed ID: 35970791
    [Abstract] [Full Text] [Related]

  • 19. Carfilzomib induction, consolidation, and maintenance with or without autologous stem-cell transplantation in patients with newly diagnosed multiple myeloma: pre-planned cytogenetic subgroup analysis of the randomised, phase 2 FORTE trial.
    Mina R, Musto P, Rota-Scalabrini D, Paris L, Gamberi B, Palmas A, Aquino S, de Fabritiis P, Giuliani N, De Rosa L, Gozzetti A, Cellini C, Bertamini L, Capra A, Oddolo D, Vincelli ID, Ronconi S, Pavone V, Pescosta N, Cea M, Fioritoni F, Ballanti S, Grasso M, Zamagni E, Belotti A, Boccadoro M, Gay F.
    Lancet Oncol; 2023 Jan 16; 24(1):64-76. PubMed ID: 36528035
    [Abstract] [Full Text] [Related]

  • 20. Alpha-interferon maintenance treatment is associated with improved survival after high-dose treatment and autologous stem cell transplantation in patients with multiple myeloma: a retrospective registry study from the European Group for Blood and Marrow Transplantation (EBMT).
    Björkstrand B, Svensson H, Goldschmidt H, Ljungman P, Apperley J, Mandelli F, Marcus R, Boogaerts M, Alegre A, Remes K, Cornelissen JJ, Bladé J, Lenhoff S, Iriondo A, Carlson K, Volin L, Littlewood T, Goldstone AH, San Miguel J, Schattenberg A, Gahrton G.
    Bone Marrow Transplant; 2001 Mar 16; 27(5):511-5. PubMed ID: 11313685
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 14.